INTRODUCTION: Direct intratumoral measurements confirm that necrosis and hypoxia are fundamental features of the pathobiology of glioblastoma (GBM). Tumor cells adapt to hypoxia through up regulation of hypoxia inducible factors (HIFs), a conserved family of transcription factors. Of the HIFs, HIF-2 alpha (HIF-2α) appears to be expressed in GBM tumor cells (not neural progenitors) and drives adaptation to prolonged (>24 hour) hypoxia. Targeting HIFs is an attractive cancer treatment strategy given that tumor hypoxia is a constant environmental cue driving genetic instability, cell migration, angiogenesis, and chemoradiation resistance. GBM, a tumor uniformly characterized by an intratumoral hypoxic environment, is a prime candidate for HIF therapeutic targeting but specific drugs were not available. PT2385 is a novel, first-in-class, HIF-2α inhibitor which recently entered clinical trials for renal carcinoma. PT2385 is orally administered and is small, lipophilic with a brain:plasma ratio of 0.9 in rats. To establish HIF-2α as a therapeutic target in GBM, we investigated in situ expression of HIF-2α protein in tissue samples from the Wake Forest Brain Tumor Center of Excellence Brain Tumor Bank. METHODS: 22 formalin-fixed, paraffin-embedded glioma samples (grade II-IV) were analyzed for HIF-2α expression using immunohistochemistry. After rehydration, endogenous peroxidase was blocked, epitopes were retrieved using a microwaved Tris EDTA pH 9.0 solution, non-specific epitopes were blocked, and HIF-2α antibody (Santa Cruz, sc-13596) was added. A horseradish peroxidase conjugated anti-mouse antibody was then added followed by detection chromagen. An inverted bright field microscope captured images and representative samples were digitally scanned. Localization and quantification of HIF-2α was independently verified by a neuropathologist. RESULTS: There was no detectable HIF-2α expression in the four Grade II and two Grade III gliomas studied. Of the 16 GBMs (Grade IV), HIF-2α was expressed in 13 (81%). HIF-2α was highly expressed in seven specimens (>10% cells positive), intermediate in six specimens (<10% of cells positive), and minimal to none in three specimens. Staining was specific to both tumor cells and occasionally monocytic cells (based on morphology). It was noted that HIF-2α was frequently present in perivascular and perinecrotic regions. CONCLUSIONS: HIF-2α expression is found in the majority of GBM specimens, but is absent in lowgrade gliomas. Immunohistochemistry demonstrated a range of HIF-2α abundance along with regional staining patterns, clustered in perivascular and perinecrotic niches. HIF-2α appears to correlate with increasing malignancy grade. This is the first in situ description of HIF-2α in gliomas and further studies are in progress for preclinical in vitro and in vivo testing of PT2385, a first-in-class HIF-2α targeted agent, in GBM.
In spite of advancements in all types of malignancy control like surgery, chemotherapy, radiotherapy, immunotherapy as well as presence of many peptides in the market for cancer control, prognosis in many types of cancer still very poor. It is enough for anybody to have a look at the main causes of death at any country to know that cancer is one of them and to discover how the challenge and defect in its treatment. Many researches aim was just the improvement of the already present methods. Here we introduce something new in the form of synthetic peptides derived from honey proteins that may overcome this challenge through direct apoptotic action on its own and not only limited to certain tumor cell line.Patent: WO/2014/040605. METHODS: to avoid any bias as being the owner of the patent, we preferred to do our experiments outside.So,the following experiments were done by Genscript company.Growth inhibitory assay was performed with 10ug, 25ug, 50ug, 75ug and 100ug of each peptide. (A+F) per well. Peptide A and peptide F were stored at -20℃. 5mg samples of peptide A and peptide F were dissolved in 500ul DPBS to make the stock solution which will be added into the wells directly. 1% TFA solution was applied as the control. a) Plate the cells into the 96 well assay plate in a density of 5000 and 10000 cells/well for adherent and suspension cell lines respectively with 50 μL complete cell culture medium. b) Add 10 μL stock solutions of the compounds into the wells. c) 10 μL 1% TFA solution was used as the control for data analyzing. d) Add 40 μL of complete medium into the wells to reach a total volume of 100μL. e) Incubate the plate at 37℃ for 72 hours. f) Add 50 μL Celltiter Glo assay mix solution to each well and mix gently at room temperature for 10 minutes, then read the luminescence with PherastarPlus (Molecular Devices). RESULTS: In vitro studies showed inhibitory effects for those peptides by themselves upon about 17 tumor cell lines out of 18 cell lines; U87MG, MDA-MB-468, K562,A375, MG63, SH-4, RD, KP1, 5637, 2774, ML-1, Cal-27, Colo-205, 769P, EOL-1, HLE, MDA-MB-436 and Calu-3 as well as the case with in vivo study in U87MG tumor mouse model.Pharmacokinetic of peptide F was also studied using 3 rats that showed very shot half life. At the moment, we try to modify and improve peptide F and other peptides to get more potent effects plus safety. who knows, we may do it.So, it is clear how those results could move the field of malignancy in general and especially gliomas management forward. OBJECTIVE: Glioblastoma is associated with poor survival and a high recurrence rate in patients due to the inevitable uncontrolled infiltrative tumor growth. The elucidation of the molecular mechanisms may offer opportunities to prevent relapses. In this study we investigated the role of the activating transcription factor 3 (ATF3) in the context of experimental nitric oxide donor (NO) treatment with JS-K (O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate) on migration of GBM cells in vitro. METHODS: RNA microarray was performed to identify ATF3 as one of the genes upregulated by experimental NO therapy in U87 glioma cells. To elucidate its role in tumor growth and treatment response of malignant gliomas, ATF3 was overexpressed by lentiviral transduction and expression of target genes STAT3 and NFκB was investigated by qRT-PCR, Western Blot and immunocytochemistry. The underlying molecular mechanisms of migration capacity and proliferation were studied by Western Blot, zymography, immunostaining and PCR while migration was assessed by wound closure and invasion assay. RESULTS: RNA microarray revealed that gene expression of ATF3 is 15-fold upregulated after exposure to 15 µM JS-K for 48 h. We demonstrate that ATF3 is directly involved in the regulation of matrix metalloproteinase expression and activation. MMP2, 7 and 9 were downregulated and MMP2 activity was reduced by overexpression of ATF3. While stat3 was 2.5-fold upregulated in cells overexpressing ATF3, STAT3 was no longer phosphorylated. Even if the expression of nfκb is not affected by ATF3, NFκB accumulated in the cytoplasm and did not translocate by TNFα stimulation. Cells overexpressing ATF3 migrated 40% slower into the gap (p=0.02) and reduced invasive capability to 30% (p=0.00004). The proliferation rate was 2-fold reduced by ATF3 (p=0.003) after 72 h whereas the influence of NO on viability did not change. CONCLUSIONS: Overexpression of ATF3 leads to a significantly reduced migration and invasion capacity by induction of tissue inhibitors of matrix metalloproteinases. ATF3 is directly involved in expression and activation of MMPs as well as the oncogenic regulators STAT3 and NFκB. Our study highlights for the first time ATF3 as a potential novel therapeutic target and can therefore be important for specific anticancer therapy to overcome the high treatment resistance of glioblastoma. 
P08.17 MITOTIC CHECKPOINT INHIBITION AUGMENTS TUMOR-TREATING-FIELD (TTFIELD) EFFECTS ON GLIOBLASTOMA CELLS

INTRODUCTION: Treatment of glioblastoma (GBM) patients with
Tumor Treating Fields (TTFields) in addition to standard therapy showed significant increase in progression free and overall survival (EF-14 trial). TTFields are alternating electric fields with low intensity (1-3V/cm) and intermediate frequency (100-400kHz) that disrupt cell division through the inhibition of spindle fiber formation. The chemotherapeutic agent Vincristine also inhibits spindle fiber formation but in contrast to TTFields, Vincristine therapy is associated with severe side effects. The spindle assembly checkpoint (SAC) diminishes the therapeutic effects of spindle damaging agents by monitoring the correct segregation of sister chromatids. An Inhibition of Monopolar spindle 1 (MPS1), the key regulator of SAC, when combined with Vincristine shows a synergistic effect on GBM growth in mice. Therefore, we hypothesized that MPS1 inhibition could increase the efficacy of TTFields. MATERIALS AND METHODS: Utilising the Novocure inovitro™ laboratory research system, 30,000 human GBM U87 cells were treated with TTFields (200kHz) alone or with 4µM of the MPS1 inhibitor MPS1-IN-3 (IN3) either alone or in combination with TTFields. Cell numbers and apoptosis (Annexin V staining) were evaluated after 24h, 48h and 72h of treatment. Cell numbers were also evaluated at 24h and 72h after end of treatment (eot). RESULTS: Treatment with TTFields plus IN3 resulted in an earlier response. After 72h, the cell number decreased by 77.5% compared to TTFields alone (p = 0.0201) and by 50% compared to MPS1-inhibition with IN3 (p = 0.0344). While the cells treated with TTFields alone
